149 related articles for article (PubMed ID: 38616265)
1. TERT RNAscope analysis of sub-centimetric papillary thyroid carcinomas and synchronous lymph node metastases.
Eich ML; Jeske W; Zenz U; Chiapponi C; Alidousty C; Merkelbach-Bruse S; Büttner R; Schultheis AM
Thyroid Res; 2024 Apr; 17(1):8. PubMed ID: 38616265
[TBL] [Abstract][Full Text] [Related]
2. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
3. Co-existence of
Ren H; Shen Y; Hu D; He W; Zhou J; Cao Y; Mao Y; Dou Y; Xiong W; Xiao Q; Zhang Y; Su X
Cancer Manag Res; 2018; 10():1005-1013. PubMed ID: 29760568
[TBL] [Abstract][Full Text] [Related]
4. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
5. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
6. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
7. Younger Than 55 Years Old and
Lai Y; Gu Y; Yu M; Deng J
Int J Gen Med; 2023; 16():1403-1414. PubMed ID: 37155469
[TBL] [Abstract][Full Text] [Related]
8. Measuring discrepancies between simple medullary and synchronous medullary/papillary thyroid carcinomas: a comparative cross-sectional study.
Zhang D; Yang M; Frattini F; Cestari A; Li K; Wang H; Chi H; Sui C; Bai K; Lan D; Dionigi G; Sun H
Front Endocrinol (Lausanne); 2023; 14():1301200. PubMed ID: 38317715
[TBL] [Abstract][Full Text] [Related]
9. Synchronous lateral lymph node metastases from papillary and follicular thyroid carcinoma: case report and review of the literature.
Stenman A; Kjellman M; Zedenius J; Juhlin CC
Thyroid Res; 2022 Feb; 15(1):1. PubMed ID: 35120551
[TBL] [Abstract][Full Text] [Related]
10. Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.
Odate T; Oishi N; Kawai M; Tahara I; Mochizuki K; Akaishi J; Ito K; Katoh R; Kondo T
Endocr Pathol; 2021 Sep; 32(3):347-356. PubMed ID: 33761111
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma].
Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160
[No Abstract] [Full Text] [Related]
12. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
14. Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients.
Shin MK; Kim JW; Min SK; Lee DJ; Kim JH; Lee SC; Chung BW; Ju YS
Oncol Lett; 2015 Sep; 10(3):1882-1888. PubMed ID: 26622769
[TBL] [Abstract][Full Text] [Related]
15. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
Lee J; Ha EJ; Roh J; Kim HK
Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
[TBL] [Abstract][Full Text] [Related]
16. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
17. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
[TBL] [Abstract][Full Text] [Related]
18. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans.
Kim SY; Kim T; Kim K; Bae JS; Kim JS; Jung CK
J Pathol Transl Med; 2020 Jul; 54(4):310-317. PubMed ID: 32527075
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
20. A prediction model incorporating the BRAF
Liu S; Liu C; Zhao L; Wang K; Li S; Tian Y; Jiao B; Gui Z; Yu T; Zhang L
Eur J Surg Oncol; 2021 Nov; 47(11):2774-2780. PubMed ID: 34483032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
